Last updated on November 2010

A Phase 3, Multi-site, randomized, mixed-blind, parallel-group treatment withdrawl and re-treatment study of the efficacy and safety of 2 oral doses of CP-690,550 in Subjects with Moderate to Severe Chronic Plaque Psoriasis


Brief description of study

A Phase 3, Multi-site, randomized, mixed-blind, parallel-group treatment withdrawl and re-treatment study of the efficacy and safety of 2 oral doses of CP-690,550 in Subjects with Moderate to Severe Chronic Plaque Psoriasis

Detailed Study Description

Patient Inclusion Criteria:

  • 18+ years of age
  • Diagnosis of stable plaque psoriasis
  • Moderate to severe
  • Covering at least 10% of total body surface area

Patient Exclusion Criteria:

  • Currently have non-plaque forms of psoriasis, eg, erythrodermic, guttate, or pustular psoriasis

Clinical Study Identifier: TX135150

Contact Investigators or Research Sites near you

Start Over

Dermatology Specialists, Inc.

Dermatology Specialists, Inc.
Oceanside, CA USA
  Connect »